Details of the Drug

General Information of Drug (ID: DMYHN59)

Drug Name
Axicabtagene ciloleucel
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Approved [1]
Large B-cell lymphoma 2A81 Approved [2]
Follicular lymphoma 2A80 Phase 2/3 [3], [4]
Mantle cell lymphoma 2A85.5 Phase 2/3 [4]
Primary mediastinal B-cell lymphoma 2A81 Phase 2/3 [3], [4]
Non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Acute lymphoblastic leukaemia 2A85 Phase 1 [4]
Drug Type
CAR T Cell Therapy
Cross-matching ID
DrugBank ID
DB13915
TTD ID
D0DK5R

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diffuse large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
9 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
10 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
11 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
12 ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
13 Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64.